Seneca Therapeutics Inc

Seneca Therapeutics Inc. is a small biotechnology company based in the United States. With a team of three employees, the company has generated $2.5 million in revenue. Founded by Dr. Paul Hallenbeck, Seneca Therapeutics is dedicated to the development of innovative cancer therapies. The company's primary focus is on Seneca Valley Virus (“SVV-001”), a groundbreaking oncolytic virus. SVV-001 has already progressed to Phase I/II clinical trials and boasts a proven safety profile in human patients. This virus exhibits a unique ability to target the TEM8 receptor, which is frequently found on various solid tumor types, including breast cancer, lung cancer, and neuroendocrine tumors. Beyond its use as a direct cancer treatment, Seneca Therapeutics is exploring the potential of SVV-001 as a viral vector for gene therapy. This innovative approach aims to deliver therapeutic genes specifically to solid tumors expressing the TEM8 receptor, offering a promising avenue for targeted cancer treatment. For more information about Seneca Therapeutics Inc. and its innovative cancer therapies, visit their website at senecatherapeutics.com.